+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

Primary Progressive Aphasia - Pipeline Insight, 2025 - Product Thumbnail Image

Primary Progressive Aphasia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Acute Unilateral Vestibulopathy (AUV) - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Unilateral Vestibulopathy (AUV) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT2A Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT2A Agonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT1A Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT1A Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT2C Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT2C Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Alpha-1 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha-1 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Alpha-2 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha-2 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
GABA Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

GABA Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT4 Partial Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT4 Partial Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT1B Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT1B Agonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Neurokinin 1 (NK1) Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Neurokinin 1 (NK1) Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Alpha-1A Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha-1A Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Neurokinin (NK) Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Neurokinin (NK) Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Cannabinoid Receptor Type 1 (CB1) Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Cannabinoid Receptor Type 1 (CB1) Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT1B Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT1B Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Endothelin Receptor A (ETA) Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Endothelin Receptor A (ETA) Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Cannabinoid Receptor Type 2 (CB2) Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Cannabinoid Receptor Type 2 (CB2) Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Prostaglandin D2 Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Prostaglandin D2 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT1D Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT1D Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more